The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains
Innovent Biologics moved its trispecific antibody IBI3003 into Phase 3 for relapsed/refractory multiple myeloma, targeting BCMA, GPRC5D, and CD3 to improve tumor targeting and reduce antigen escape. Bionyra Pharma raised $165 million to develop two TL1A‑targeting biologics for inflammatory bowel disease, underscoring investor confidence in the pathway. Insilico Medicine partnered with SK Biopharmaceuticals to apply AI platforms to neuroimmune and CNS drug discovery, expanding AI’s role beyond early‑stage screening. Together, these moves illustrate a convergence of advanced biologics and AI in tackling hard‑to‑treat diseases.
Takeda to Deploy Boltz Biomolecular AI Models in Drug Discovery Research
Takeda has entered a research collaboration with US‑based AI lab Boltz to deploy the company’s biomolecular models, BoltzMol‑1 and BoltzProt‑1, across its preclinical discovery organization. The partnership provides Takeda scientists with access via the Boltz Lab interface, APIs and large‑language‑model...
Japan Approves Subcutaneous Formulation of Sanofi's Sarclisa for Multiple Myeloma, Marking Second Global Regulatory Win
Sanofi’s anti‑CD38 antibody Sarclisa (isatuximab) received Japanese regulatory approval on June 19 2026 for a subcutaneous (SC) formulation across three multiple myeloma regimens, marking the second global endorsement after the EU. The SC version is a fixed 1,400 mg dose that can be...
The BioPharm Brief: FDA Decisions, Vaccine Momentum, and Lymphoma Advances
The FDA has accepted Roche's supplemental biologics license application for a Lunsumio and Polivy combination targeting relapsed or refractory large B‑cell lymphoma, citing improved progression‑free survival. Merck secured approval to expand its 21‑valent CAPVAXIVE pneumococcal vaccine to high‑risk children aged...
Cencora Experts Discuss Regulatory and Supply Chain Challenges in Radiopharmaceutical Distribution
Cencora’s senior logistics leaders highlighted the growing complexity of distributing radiopharmaceuticals, which must meet both pharmaceutical quality regulations and hazardous‑material transport rules. Divergent national interpretations of international guidance create clearance delays, threatening the narrow delivery windows dictated by the drugs’...
Bambusa Reports Positive Phase 1 Data for Dual-Targeting Bispecific Antibody BBT002 in Type 2 Inflammatory Diseases
Bambusa Therapeutics announced positive Phase 1 multiple ascending dose data for its bispecific antibody BBT002, which simultaneously targets IL‑4Rα and IL‑5. The study in healthy volunteers demonstrated rapid, deep and sustained reductions in eosinophils, TARC and pSTAT6, with biomarker suppression lasting...
Talquetamab Plus Daratumumab Combination Reduces Progression Risk by Up to 72% in Phase 3 Relapsed Multiple Myeloma Trial
Johnson & Johnson’s phase 3 MonumenTAL‑3 trial showed that talquetamab (Talvey) combined with subcutaneous daratumumab‑hyaluronidase, with or without pomalidomide, dramatically improved outcomes for relapsed/refractory multiple myeloma. At 24 months, progression‑free survival reached 81.3% versus 51.2% and overall survival 89.2% versus 79.1% compared...
The BioPharm Brief: Hormones, Metabolism, Momentum
The BioPharm Brief highlighted new data from three biotech programs. MBX Biosciences reported that 57% of patients maintained response after one year on its once‑weekly PTH replacement, canvuparatide, positioning it for a Phase 3 start later this year. Gan & Lee Pharmaceuticals...
The BioPharm Brief: CAR-T Progress, ADC Momentum, Biosimilar Expansion
Imviva Biotech presented data on its off‑the‑shelf CAR‑T candidate CTD402, reporting an 86% overall response rate in adult relapsed/refractory T‑ALL and an 80% complete remission rate in pediatric patients. Immunome dosed the first patient in a Phase 1 trial of IM‑1617,...
The Ron Lanton Report: From Innovation to Infrastructure
In the latest Ron Lanton Report, insights from the JP Morgan Healthcare Conference reveal a pivot in health‑care investing. Capital is moving away from early‑stage novelty toward companies that can scale, survive regulatory and reimbursement pressures, and embed technology into core...
BioPharm Brief: RNAi, Obesity, and Diabetes Advances
City Therapeutics secured a $99.5 million Series B round to accelerate its next‑generation RNAi platform, including the Phase 1 CITY‑FXI program for thromboembolic disease and a Stargardt disease candidate. Boehringer Ingelheim and Zealand Pharma reported that survodutide, a dual glucagon/GLP‑1 agonist, achieved significant...
The BioPharm Brief: Myeloma, Hemophilia, and KRAS
Sanofi received European Commission approval for a subcutaneous formulation of isatuximab (Sarclisa) for all its existing multiple myeloma indications, offering a shorter administration route. The FDA expanded Pfizer’s HYMPAVZI to include children aged 6‑11 and patients with hemophilia A or...
TIGIT Review Highlights Unresolved Questions for Pancreatic Cancer Immunotherapy
A June 5 review in the Journal of Pancreatology re‑examines TIGIT as an immune‑checkpoint target, highlighting its mechanistic appeal but noting the lack of solid‑tumor efficacy data. Early phase 2 results from the CITYSCAPE trial showed benefit of tiragolumab plus atezolizumab in...
Becoming a Cornerstone of Fujifilm’s CDMO Strategy in Denmark
Fujifilm is positioning its new contract development and manufacturing organization (CDMO) site in Denmark as a central pillar of its global strategy. The facility leverages early supply‑chain engagement and a continuous‑improvement model to lower risk, speed tech transfer, and shorten...
A Q&A with Dr. Ganesh Bala on LC–MS and Multi-Attribute Methods for Bioconjugate CQA Monitoring
Agilent’s Dr. Ganesh Bala explained that multi‑attribute methods (MAMs) using LC‑MS peptide mapping have become a core analytical platform for monitoring critical quality attributes of antibody‑drug conjugates (ADCs) and other bioconjugates. He highlighted the growing heterogeneity of these molecules—variable conjugation sites,...